29.01.2013 - Belgian cell therapeutics developer Bone Therapeutics SA has secured €7.7m in a Series D financing.
The Gosselies-based company raised €6.1m from existing investors plus €1.6m in grant subsidies from the Walloon Region. Bone Therapeutics announced that they will use the fresh capital to accelerate its bone cell therapy programmes, especially its Phase III lead product PREOB®, an autologous bone-forming (osteoblastic) cell therapy for the treatment of osteonecrosis and non-union fractures.
The company announced it will also use the funds to push the development of two preclinical products. ALLOB® is an allogeneic bone cell therapy product, which is expected to enter the clinic in 2013. MXB is a preclinical combined cell-matrix product for the treatment of large bone defects. All cellular therapies of the Belgian company require a minimally invasive administration technique, avoiding the need for surgery.
The Series D round was supported by Nausicaa Ventures, BAMS Angels Fund I and Life Science Research Partners as well as the Société Régionale d'Investissement de Wallonie (SRIW) and Sambrinvest, two supportive Walloon Region controlled minority shareholders. According to Bone Therapeutics, the bone disease and reconstruction market is one of the largest healthcare markets in the world, with more than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone but few players that address bone regeneration.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.